MedTrace Logo

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

NCT00359762 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1029

Last updated 2015-09-15

Study results available
· View outcomes & findings →

Summary

This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.

Conditions

Interventions

DRUG

exenatide

subcutaneous injection (5mcg or 10mcg), twice a day

DRUG

glimepiride

oral tablet (titrated to maximally tolerated dose), once daily

Sponsors & Collaborators

Principal Investigators

  • James Malone, MD · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Austria
  • Czechia
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Israel
  • Italy
  • Mexico
  • Poland
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00359762 on ClinicalTrials.gov